Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
|Slideshows|August 8, 2022
August 8 is National CBD Day 2022
Author(s)Psychiatric Times Editors
In honor of National CBD Day, Psychiatric Times™ shares some recent expert discussions on the pros, cons, and clinical implications of cannabis use in psychiatry.
Advertisement
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
2
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
3
Responding to Intimate Partner Violence Disclosures in Psychiatry
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5